The single-arm, phase 2 SAKK 06/17 trial analyzed the addition of neoadjuvant durvalumab to gemcitabine/cisplatin chemotherapy in patients with muscle-invasive bladder cancer (MIBC) followed by radical surgery and adjuvant checkpoint inhibition with durvalumab. The study analyzed 54 cisplatin-fit patients with stage cT2-T4a cN0-1 operable MIBC from 12 treatment sites. Patients were administered 4 cycles of neoadjuvant gemcitabine/cisplatin combined with 4 cycles of durvalumab (starting at the second gemcitabine/cisplatin cycle) followed by radical surgery. Adjuvant durvalumab was administered for 10 ...
Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
Dr. Sonpavde expounds on the current state and momentum of research efforts to advance treatment strategies in MIBC.
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Dr. Satkunasivam details the RAD VACCINE MIBC trial, an evaluation of the efficacy and safety of neoadjuvant sasanlimab.
Dr. Satkunasivam explains the momentum for an IO-plus-radiation strategy in MIBC, as well as the potential of sasanlimab.
The COXEN model is used to select genes for predicting tumor cell response to a specific drug treatment.
dd-MVAC provides a better OS at 5 years compared with GC in the perioperative setting for patients with MIBC.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. McKay discusses upcoming prostate cancer data to be presented at ESMO and discussed at The Uromigos: Live & Unplugged.
Dr. Gupta also discusses upcoming bladder cancer data from ESMO that will influence debate and discussion at the event.
Dr. Petros Grivas shares what data he's most looking forward to discussing at the second Uromigos: Live & Unplugged event.
The second annual Uromigos: Live & Unplugged event will take place in Nashville, Tennessee, on November 3-4.
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
Advertisement
Advertisement
Trending
The first PET scans using Illuccix, Telix’s PSMA-PET imaging agent, have been carried out in cooperation with BAMF Health.
Nanobubbles can target membrane proteins, including PSMA, to bind to receptors that are overexpressed in cancer cells.
Few biomarkers predict therapeutic response to radiation or adjunctive treatments in PCa patients treated with radiotherapy.
